Effect of S‐1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7‐year multicenter observational cohort study in Taiwan
Abstract Objective Studies have rarely explored the efficacy of S‐1 in treating advanced pancreatic cancer outside Japan. This study compared the survival outcomes of patients with advanced pancreatic cancer treated with S‐1 with the survival outcomes of those without S‐1 treatment before and after...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-05-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2094 |
| _version_ | 1797236935606927360 |
|---|---|
| author | Hsiang‐Lan Lai Yen‐Yang Chen Chang‐Hsien Lu Chia‐Yen Hung Yung‐Chia Kuo Jen‐Shi Chen Hung‐Chih Hsu Ping‐Tsung Chen Pei‐Hung Chang Yu‐Shin Hung Wen‐Chi Chou |
| author_facet | Hsiang‐Lan Lai Yen‐Yang Chen Chang‐Hsien Lu Chia‐Yen Hung Yung‐Chia Kuo Jen‐Shi Chen Hung‐Chih Hsu Ping‐Tsung Chen Pei‐Hung Chang Yu‐Shin Hung Wen‐Chi Chou |
| author_sort | Hsiang‐Lan Lai |
| collection | DOAJ |
| description | Abstract Objective Studies have rarely explored the efficacy of S‐1 in treating advanced pancreatic cancer outside Japan. This study compared the survival outcomes of patients with advanced pancreatic cancer treated with S‐1 with the survival outcomes of those without S‐1 treatment before and after S‐1 reimbursement was introduced in Taiwan in June of 2014. Method We retrospectively analyzed 838 patients with locally advanced or metastatic pancreatic cancer who underwent palliative chemotherapy from 2010 to 2016 at 4 institutes in Taiwan. For survival analysis, patients were categorized into two groups according to whether they received S‐1 treatment as palliative chemotherapy after diagnosis: (a) S‐1‐treated (n = 335) and (b) non‐S‐1‐treated (n = 503) groups. Results The median overall survival was longer in the S‐1‐treated group than in the non‐S‐1‐treated group (10.7 vs 6.0 mo, P < 0.001). Subgroup survival analyses showed that the S‐1‐treated group had more favorable outcomes than the non‐S‐1‐treated group in terms of stage III (19.6 vs 10.1 mo, P < 0.001) and stage IV (8.5 vs 5.3 mo, P < 0.001) disease. The disease control rates were 43.6% and 32.8% (P < 0.001) in patients treated with and without S‐1 in the first‐line setting, respectively. In multivariate analysis, exposure to S‐1 treatment was an independent prognosticator for survival. Conclusion Our results support the clinical use of S‐1 as the treatment of choice for patients with locally advanced or metastatic pancreatic cancer, particularly in resource‐limited situations. |
| first_indexed | 2024-04-24T17:11:45Z |
| format | Article |
| id | doaj.art-8961c7e318354b0f8d36b67ef0e76d18 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-24T17:11:45Z |
| publishDate | 2019-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-8961c7e318354b0f8d36b67ef0e76d182024-03-28T10:30:35ZengWileyCancer Medicine2045-76342019-05-01852085209410.1002/cam4.2094Effect of S‐1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7‐year multicenter observational cohort study in TaiwanHsiang‐Lan Lai0Yen‐Yang Chen1Chang‐Hsien Lu2Chia‐Yen Hung3Yung‐Chia Kuo4Jen‐Shi Chen5Hung‐Chih Hsu6Ping‐Tsung Chen7Pei‐Hung Chang8Yu‐Shin Hung9Wen‐Chi Chou10Division of Oncology Chang Gung Memorial Hospital at Kaohsiung Kaohsiung TaiwanDivision of Oncology Chang Gung Memorial Hospital at Kaohsiung Kaohsiung TaiwanDivision of Oncology Chang Gung Memorial Hospital at Chiayi Chiayi TaiwanDivision of Oncology Chang Gung Memorial Hospital at Linkou Taoyuan TaiwanDivision of Oncology Chang Gung Memorial Hospital at Linkou Taoyuan TaiwanDivision of Oncology Chang Gung Memorial Hospital at Linkou Taoyuan TaiwanDivision of Oncology Chang Gung Memorial Hospital at Linkou Taoyuan TaiwanDivision of Oncology Chang Gung Memorial Hospital at Chiayi Chiayi TaiwanDivision of Oncology Chang Gung Memorial Hospital at Keelung Keelung TaiwanDivision of Hematology Chang Gung Memorial Hospital at Linkou Taoyuan TaiwanDivision of Oncology Chang Gung Memorial Hospital at Linkou Taoyuan TaiwanAbstract Objective Studies have rarely explored the efficacy of S‐1 in treating advanced pancreatic cancer outside Japan. This study compared the survival outcomes of patients with advanced pancreatic cancer treated with S‐1 with the survival outcomes of those without S‐1 treatment before and after S‐1 reimbursement was introduced in Taiwan in June of 2014. Method We retrospectively analyzed 838 patients with locally advanced or metastatic pancreatic cancer who underwent palliative chemotherapy from 2010 to 2016 at 4 institutes in Taiwan. For survival analysis, patients were categorized into two groups according to whether they received S‐1 treatment as palliative chemotherapy after diagnosis: (a) S‐1‐treated (n = 335) and (b) non‐S‐1‐treated (n = 503) groups. Results The median overall survival was longer in the S‐1‐treated group than in the non‐S‐1‐treated group (10.7 vs 6.0 mo, P < 0.001). Subgroup survival analyses showed that the S‐1‐treated group had more favorable outcomes than the non‐S‐1‐treated group in terms of stage III (19.6 vs 10.1 mo, P < 0.001) and stage IV (8.5 vs 5.3 mo, P < 0.001) disease. The disease control rates were 43.6% and 32.8% (P < 0.001) in patients treated with and without S‐1 in the first‐line setting, respectively. In multivariate analysis, exposure to S‐1 treatment was an independent prognosticator for survival. Conclusion Our results support the clinical use of S‐1 as the treatment of choice for patients with locally advanced or metastatic pancreatic cancer, particularly in resource‐limited situations.https://doi.org/10.1002/cam4.2094palliative chemotherapypancreatic cancerS‐1survival outcome |
| spellingShingle | Hsiang‐Lan Lai Yen‐Yang Chen Chang‐Hsien Lu Chia‐Yen Hung Yung‐Chia Kuo Jen‐Shi Chen Hung‐Chih Hsu Ping‐Tsung Chen Pei‐Hung Chang Yu‐Shin Hung Wen‐Chi Chou Effect of S‐1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7‐year multicenter observational cohort study in Taiwan Cancer Medicine palliative chemotherapy pancreatic cancer S‐1 survival outcome |
| title | Effect of S‐1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7‐year multicenter observational cohort study in Taiwan |
| title_full | Effect of S‐1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7‐year multicenter observational cohort study in Taiwan |
| title_fullStr | Effect of S‐1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7‐year multicenter observational cohort study in Taiwan |
| title_full_unstemmed | Effect of S‐1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7‐year multicenter observational cohort study in Taiwan |
| title_short | Effect of S‐1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7‐year multicenter observational cohort study in Taiwan |
| title_sort | effect of s 1 on survival outcomes in 838 patients with advanced pancreatic cancer a 7 year multicenter observational cohort study in taiwan |
| topic | palliative chemotherapy pancreatic cancer S‐1 survival outcome |
| url | https://doi.org/10.1002/cam4.2094 |
| work_keys_str_mv | AT hsianglanlai effectofs1onsurvivaloutcomesin838patientswithadvancedpancreaticcancera7yearmulticenterobservationalcohortstudyintaiwan AT yenyangchen effectofs1onsurvivaloutcomesin838patientswithadvancedpancreaticcancera7yearmulticenterobservationalcohortstudyintaiwan AT changhsienlu effectofs1onsurvivaloutcomesin838patientswithadvancedpancreaticcancera7yearmulticenterobservationalcohortstudyintaiwan AT chiayenhung effectofs1onsurvivaloutcomesin838patientswithadvancedpancreaticcancera7yearmulticenterobservationalcohortstudyintaiwan AT yungchiakuo effectofs1onsurvivaloutcomesin838patientswithadvancedpancreaticcancera7yearmulticenterobservationalcohortstudyintaiwan AT jenshichen effectofs1onsurvivaloutcomesin838patientswithadvancedpancreaticcancera7yearmulticenterobservationalcohortstudyintaiwan AT hungchihhsu effectofs1onsurvivaloutcomesin838patientswithadvancedpancreaticcancera7yearmulticenterobservationalcohortstudyintaiwan AT pingtsungchen effectofs1onsurvivaloutcomesin838patientswithadvancedpancreaticcancera7yearmulticenterobservationalcohortstudyintaiwan AT peihungchang effectofs1onsurvivaloutcomesin838patientswithadvancedpancreaticcancera7yearmulticenterobservationalcohortstudyintaiwan AT yushinhung effectofs1onsurvivaloutcomesin838patientswithadvancedpancreaticcancera7yearmulticenterobservationalcohortstudyintaiwan AT wenchichou effectofs1onsurvivaloutcomesin838patientswithadvancedpancreaticcancera7yearmulticenterobservationalcohortstudyintaiwan |